MedTrace Logo

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)

NCT04876313 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2022-04-06

No results posted yet for this study

Summary

To assess whether nivolumab+nab-paclitaxel combination results in patients with muscle-invasive bladder cancer

Conditions

  • Muscle-Invasive Bladder Carcinoma

Interventions

DRUG

Nivolumab + Nab-paclitaxel

4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8

DRUG

Nivolumab

360 mg IV Q3W x 13 cycles

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-27
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04876313 on ClinicalTrials.gov